The global immunohistochemistry (IHC) market is poised for significant growth, with an expected value of USD 3.5 billion in 2024. With a projected moderate compound annual growth rate (CAGR) of 7.8%, the market is forecast to expand to USD 7.4 billion by 2034, reflecting its increasing role in both diagnostic and therapeutic applications.
Immunohistochemistry has long been a critical tool in the diagnosis of various diseases, particularly oncology. Recent advancements, particularly in multiplexing techniques, have revolutionized the field, allowing for the simultaneous detection of multiple biomarkers. This technological leap is improving diagnostic accuracy and providing healthcare professionals with deeper insights into disease pathology.
Furthermore, the integration of artificial intelligence (AI) and digital pathology is enhancing the efficiency and precision of immunohistochemistry workflows. AI-driven platforms are enabling faster image analysis, thereby boosting diagnostic throughput and minimizing human error, which is essential for clinical settings where accuracy is paramount.
One of the major growth drivers of the IHC market is the rise of companion diagnostic assays, which have played a crucial role in advancing immunotherapy trials, especially in oncology. These assays are increasingly being incorporated into drug development, enabling the identification of patients most likely to benefit from specific treatments, thus driving the market’s expansion.
As quality control and standardization continue to be a priority, the reliability and repeatability of immunohistochemistry assays are improving. This trend is contributing to the overall growth of the market, as laboratories and healthcare providers seek consistent, reproducible results to guide clinical decisions.
The therapeutic and research influence of immunohistochemistry is not confined to oncology alone. It is gaining importance across a range of disciplines, including immunology, neuroscience, and infectious diseases. With its ability to provide in-depth insights into disease mechanisms, immunohistochemistry is poised to play a pivotal role in the development of novel therapies and diagnostics in these areas.
As the market continues to evolve, the demand for advanced, reliable, and efficient immunohistochemistry solutions is set to surge, fueling growth and driving innovations across the healthcare sector.
Key Takeaways:
- Market Growth: The global immunohistochemistry (IHC) market is expected to reach a value of USD 3.5 billion in 2024, with a CAGR of 7.8% forecasted from 2024 to 2034, leading to a projected market size of USD 7.4 billion by 2034.
- United States Demand: Rising research activities, especially in precision medicine, are driving IHC demand in the United States. With a forecasted CAGR of 8%, the U.S. benefits from strong collaborations between academic, biotechnology, and healthcare sectors, boosting IHC in molecular target identification and treatment selection.
- China’s Growth: The immunohistochemistry market in China is predicted to grow at a CAGR of 8.5%, fueled by aging demographics, lifestyle changes, and increased cancer rates. Government investments in healthcare infrastructure are expanding access to cancer diagnosis and treatment, making IHC a vital tool in improving patient outcomes.
- Technological Advances in Japan: Japan is expected to lead the IHC market with a CAGR of 9.2% due to advances in biomedical imaging, particularly digital pathology and molecular imaging. These technologies are enhancing the accuracy of disease characterization and tailored treatment plans, especially for geriatric patients.
- South Korea’s Investments: South Korea’s CAGR of 9.3% is driven by increased healthcare spending and investments in advanced diagnostic technologies. IHC plays a pivotal role in cancer diagnosis and treatment planning, especially with an aging population and rising cancer incidences.
- United Kingdom’s Focus on Early Detection: The United Kingdom is set to grow at a CAGR of 9.1%, driven by a strong biomedical research community and a national focus on early disease detection and prevention. IHC is increasingly used for early cancer detection, enabling better patient outcomes through timely interventions and targeted therapies.
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Competitive Landscape:
Immunohistochemistry (IHC) companies are increasingly pursuing collaborations and strategic partnerships to enhance their capabilities. The importance of healthcare partnerships continues to grow as the industry recognizes the value of collaboration in delivering innovative medical treatments to patients globally.
Key Market Developments:
In March 2023, Aptamer Group plc introduced its newly developed IHC reagent, Optimer®-Fc. To validate the Optimer-Fc platform, Aptamer partnered with one of the top three IHC companies. Additionally, several pharmaceutical and biotech firms are advancing the development of IHC Optimer binders.
In September 2023, Ibex Medical Analytics, a global leader in AI-driven cancer diagnostics, launched Galen™ Breast HER2. This AI-powered solution assists pathologists in providing accurate and reproducible HER2 scores for breast cancer patients, revolutionizing diagnostic precision through artificial intelligence.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd.
- Merck KGaA
- Danaher Corporation
- Perkinelmer Inc.
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- Bio SB
- Agilent Technologies Inc.
- Abcam plc.
Immunohistochemistry (IHC) – Key Segments:
By Product:
- Antibodies
- Primary Antibodies
- Secondary Antibodies
- Equipment
- Slide Staining System
- Tissue Microarrays
- Tissue Processing Systems
- Slide Scanners
- Others
- Reagents
- Histological stains
- Blocking Sera & Reagents
- Chromogenic Substrates
- Fixation Reagents
- Organic Solvents
- Proteolytic Enzymes
- Diluents
- Other Reagents
- Kits
By Application:
- Diagnostics
- Cancer
- Infectious Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Diabetes Mellitus
- Nephrological Diseases
- Research
By End User:
- Hospitals & Diagnostic Laboratories
- Research Institutes
- Others
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube